Anti-spasticity agents for multiple sclerosis
is a topic covered in the Evidence-Based Medicine Guidelines
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
"Anti-spasticity Agents for Multiple Sclerosis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis.
Anti-spasticity agents for multiple sclerosis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis. Accessed October 22, 2019.
Anti-spasticity agents for multiple sclerosis. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis
Anti-spasticity Agents for Multiple Sclerosis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 October 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis.
TY - ELEC
T1 - Anti-spasticity agents for multiple sclerosis
ID - 451024
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine